



Background




- Monoacylglycerol acyltransferase (MGAT2) has been implicated in the development of metabolic disorders
- MGAT2 inhibition has emerged as a potential treatment for obesity, type II diabetes and other disorders.
- MGAT2 deficiency has been linked to increased energy expenditure and protects genetically obese mice from weight gain.
- HTS of MGAT2 inhibitors identified an initial hit which was further optimized through SAR studies.
- Currently in preclinical trials



Initial Route



Improved Pilot Route



SAR Approach

